Global Dexlansoprazole Sustained Release Capsule Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dexlansoprazole Sustained Release Capsule Market Research Report 2024
Dexlansoprazole sustained-release capsules were approved by the U.S. FDA in January 2009, under the trade name DEXILANT. For the treatment of heartburn caused by non-erosive gastroesophageal reflux disease (GERD), erosive esophagitis (EE) and maintenance treatment after healing of erosive esophagitis, all of which are administered once a day.
According to Mr Accuracy reports’s new survey, global Dexlansoprazole Sustained Release Capsule market is projected to reach US$ 428.1 million in 2034, increasing from US$ 298 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dexlansoprazole Sustained Release Capsule market research.
Key manufacturers engaged in the Dexlansoprazole Sustained Release Capsule industry include TAKEDA PHARM, PAR PHARM and TWI PHARM, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Dexlansoprazole Sustained Release Capsule were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Dexlansoprazole Sustained Release Capsule market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dexlansoprazole Sustained Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
TAKEDA PHARM
PAR PHARM
TWI PHARM
Segment by Type
30MG
60MG
Hospital
Clinic
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Dexlansoprazole Sustained Release Capsule report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Dexlansoprazole Sustained Release Capsule market is projected to reach US$ 428.1 million in 2034, increasing from US$ 298 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dexlansoprazole Sustained Release Capsule market research.
Key manufacturers engaged in the Dexlansoprazole Sustained Release Capsule industry include TAKEDA PHARM, PAR PHARM and TWI PHARM, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Dexlansoprazole Sustained Release Capsule were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Dexlansoprazole Sustained Release Capsule market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dexlansoprazole Sustained Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
TAKEDA PHARM
PAR PHARM
TWI PHARM
Segment by Type
30MG
60MG
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Dexlansoprazole Sustained Release Capsule report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices